| name | endo-discontinue-longacting-srl-pegvisomant-preconception |
| description | This skill guides discontinuation of long-acting somatostatin receptor ligands (SRLs) and pegvisomant approximately two months before conception attempts in patients with acromegaly, substituting short-acting octreotide as needed for disease control. Trigger phrases include "preconception planning," "patient planning pregnancy," or "about to attempt conception." |
Discontinue long-acting SRL and pegvisomant approximately 2 months before conception attempts
STEP 1 — Gather Information
Confirm diagnosis of acromegaly, current medical therapy (long-acting SRL such as octreotide LAR or lanreotide autogel, or pegvisomant), pregnancy intent, and desired conception timeline.
STEP 2 — Rule In / Rule Out
Is the patient currently receiving a long-acting SRL or pegvisomant and actively planning pregnancy or attempting conception? If yes, proceed to Step 3; if not on these agents or not pursuing conception, no discontinuation is needed.
STEP 3 — Classify or Stratify
Determine the approximate discontinuation date: calculate 2 months prior to the intended conception date; if within this window, classify as ready for transition.
STEP 4 — Decide
Discontinue the long-acting SRL and pegvisomant; initiate short-acting octreotide (e.g., 50–100 mcg subcutaneously every 8 hours as needed) to maintain biochemical control until conception is confirmed, then reassess therapy.
Clinical Guardrails / Mimics / Pitfalls
Do not continue long-acting SRL or pegvisomant during pregnancy due to insufficient safety data; avoid relying on depot formulations for contraception; monitor IGF-1 and symptoms frequently during transition; short-acting octreotide crosses the placenta—use lowest effective dose.
Concrete Clinical Example
A 32-year-old woman on octreotide LAR 30 mg monthly planning pregnancy stops the depot two months before her target conception date and uses short-acting octreotide 50 mcg SC TID as needed to keep IGF-1 <1.3× ULN until pregnancy test is positive.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
